Aligos Therapeutics, Inc. (ALGS)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Aligos Therapeutics, Inc. (ALGS) is down 44.9% since the beginning of the year. At $5 per share, ALGS is trading 62.5% below its 52-week high of $14. Investors who bought $1,000 worth of ALGS shares 5 years ago would now be looking at an investment worth $7.

Aligos Therapeutics, Inc. (ALGS) has returned -44.85% so far this year and -13.61% over the past 12 months.

Based on dividend-adjusted daily data since Oct 16, 2020, ALGS's average daily return is -0.10%, while the average monthly return is -1.15%.

Historically, 38% of months were positive and 62% were negative. The best month was Nov 2024 with a return of +160.8%, while the worst month was Jan 2022 at -73.1%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.

On a daily basis, ALGS closed higher 46% of trading days. The best single day was Sep 9, 2024 with a return of +55.3%, while the worst single day was Jan 6, 2022 at -56.7%.

Aligos Therapeutics, Inc. has an annualized alpha of -37.57%, beta of 1.43, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since October 19, 2020.

• This stock participated in 245.62% of S&P 500 Index downside but only 17.06% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ALGS ranks 36 for risk / return — below 36% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Aligos Therapeutics, Inc. (ALGS) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Aligos Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Aligos Therapeutics, Inc. was 99.54%, occurring on Apr 10, 2025. The portfolio has not yet recovered.

The current Aligos Therapeutics, Inc. drawdown is 99.41%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Aligos Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Aligos Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.